{"filing":{"accession_number":"0001193125-26-332752","cik":"0001863127","ticker":"TYRA","company_name":"Tyra Biosciences, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"tyra-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-20260804.htm"},"events":[{"id":23888,"run_id":21605,"accession_number":"0001193125-26-332752","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial results including cash position ($353.9M), R\u0026D expenses ($39.2M), G\u0026A expenses ($9.8M), and net loss ($45.6M), along with condensed balance sheets and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and cash runway.","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24244,"accession_number":"0001193125-26-332752","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial results including cash position ($353.9M), R\u0026D expenses ($39.2M), G\u0026A expenses ($9.8M), and net loss ($45.6M), along with condensed balance sheets and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:28.009896+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24244,"accession_number":"0001193125-26-332752","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial results including cash position ($353.9M), R\u0026D expenses ($39.2M), G\u0026A expenses ($9.8M), and net loss ($45.6M), along with condensed balance sheets and operational highlights. This is a standard quarterly earnings disclosure material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:25:28.009896+00:00","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-08-04"}]}